Quiz

Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia

Craig Chepke, MD, DFAPA

09/12/2025

Reference
Chepke C. Considerations for incorporating muscarinic agonists into schizophrenia treatment. Psych Congress Network. August 5, 2025. Accessed September 12, 2025.

Related Content

spilled bottle of white pills

News

Tazbentetol Demonstrates Early Symptom Improvement in Phase 2 Schizophrenia Trial

04/01/2026

Maria Mantas

Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.

Interim results from a phase 2 randomized, double-blind, placebo-controlled trial of tazbentetol demonstrated early signals of efficacy across schizophrenia symptom domains.

Interim results from a phase 2...

04/01/2026

Psych Congress Network

Sponsored

Infographic

Clinician Ranking of Olanzapine Tolerability & Adverse Event Mitigation Strategies in Real-World Practice

03/30/2026

This infographic focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such...

This infographic focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such...

This infographic focuses on...

03/30/2026

Psych Congress Network

Sponsored

Videos

SONAR Survey: Perceptions of Tolerability & Adverse Event Mitigation

03/30/2026

Andrew J. Cutler, MD; Peter J. Weiden, MD, PhD

This video focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such as...

This video focuses on clinician perceptions of adverse events associated with the use of olanzapine and how they rated proposed strategies to help maintain therapy when it is otherwise effective. It covers clinician-ranked options such as...

This video focuses on clinician...

03/30/2026

Psych Congress Network

Sponsored

Infographic

Clinician Perceptions of Olanzapine

03/30/2026

This infographic reviews clinician perceptions of where a commonly used second-generation antipsychotic performs best. It also outlines common clinical scenarios in which respondents report preferring this option, translating perceptions into...

This infographic reviews clinician perceptions of where a commonly used second-generation antipsychotic performs best. It also outlines common clinical scenarios in which respondents report preferring this option, translating perceptions into...

This infographic reviews...

03/30/2026

Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Amber Hoberg

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, MSN, APRN, PMHNP-BC

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Hoberg and Matthews

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Do clinicians need to test for...

04/03/2024

Psych Congress NP Institute